Literature DB >> 21964303

Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia.

Katherine A High, Mark W Skinner.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21964303      PMCID： PMC3188754          DOI： 10.1038/mt.2011.203

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  9 in total

Review 1.  Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism.

Authors:  B L Evatt; L Robillard
Journal:  Haemophilia       Date:  2000-05       Impact factor: 4.287

2.  HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.

Authors:  J G POOL; E J GERSHGOLD; A R PAPPENHAGEN
Journal:  Nature       Date:  1964-07-18       Impact factor: 49.962

Review 3.  The tragic history of AIDS in the hemophilia population, 1982-1984.

Authors:  B L Evatt
Journal:  J Thromb Haemost       Date:  2006-09-14       Impact factor: 5.824

4.  Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

Authors:  I M Nilsson; E Berntorp; T Löfqvist; H Pettersson
Journal:  J Intern Med       Date:  1992-07       Impact factor: 8.989

Review 5.  Can haemophilic arthropathy be prevented?

Authors:  R C Ljung
Journal:  Br J Haematol       Date:  1998-05       Impact factor: 6.998

6.  Hepatitis and clotting-factor concentrates.

Authors:  C K Kasper; S A Kipnis
Journal:  JAMA       Date:  1972-07-31       Impact factor: 56.272

7.  CD8(+) T-cell responses to adeno-associated virus capsid in humans.

Authors:  Federico Mingozzi; Marcela V Maus; Daniel J Hui; Denise E Sabatino; Samuel L Murphy; John E J Rasko; Margaret V Ragni; Catherine S Manno; Jurg Sommer; Haiyan Jiang; Glenn F Pierce; Hildegund C J Ertl; Katherine A High
Journal:  Nat Med       Date:  2007-03-18       Impact factor: 53.440

8.  Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.

Authors:  M Manco-Johnson
Journal:  Haemophilia       Date:  2007-09       Impact factor: 4.287

9.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440
  9 in total
  4 in total

1.  Gene therapy for hemophilia: the clot thickens.

Authors:  Katherine A High
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

2.  Perspective: The fix is in.

Authors:  Stephen Pemberton
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Gene therapy for hemophilia: addressing the coming challenges of affordability and accessibility.

Authors:  Mark W Skinner
Journal:  Mol Ther       Date:  2013-01       Impact factor: 11.454

Review 4.  Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs.

Authors:  Timothy C Nichols; Margaret H Whitford; Valder R Arruda; Hansell H Stedman; Mark A Kay; Katherine A High
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.